An Active-comparator-controlled, Open-label, Parallel Group Study to Evaluate the Effect of Survodutide on Energy Expenditure and Fatty Acid Oxidation in Subjects With Obesity

This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy and breaks down fat. This study compares survodutide with another medicine called semaglutide. Survodutide is being developed to treat people with obesity.
Semaglutide is already used to treat people with obesity.
Participants are put into 2 groups by chance. One group gets survodutide and the other group gets semaglutide. Participants get survodutide or semaglutide as an injection under the skin once a week. Participants are in the study for 8-10 months depending on how long the treatment is given. During this time, they visit the study site weekly. Some of the visits may also be done at the participant's home instead of the study site.
At some of the visits, doctors test how much energy a participant's body uses. This is done in a special room where they measure the oxygen that is breathed in and the carbon dioxide that is breathed out by the participant. The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date08 Apr 2025

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT06772532

/ Active, not recruitingPhase 1

Relative Bioavailability of Three Different BI 456906 Formulations Following Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Trial)

The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.

Start Date10 Feb 2025

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT06632457

/ RecruitingPhase 3

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

This study is open to adults who are at least 18 years old and have:
* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or
* A confirmed liver disease called metabolic-associated steatohepatitis (MASH)
* BMI of 27 kg/m2 or more or
* 25 kg/m2 or more if the participant is Asian.
People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function.
Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly.
Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study.
The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.

Start Date02 Dec 2024

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Survodutide

100 Translational Medicine associated with Survodutide

100 Patents (Medical) associated with Survodutide

Literatures (Medical) associated with Survodutide

01 Jun 2025·ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD

Review

Author: Tavaglione, Federica ; Zafer, Maryam ; Loomba, Rohit ; Romero‐Gómez, Manuel

ABSTRACT:

Background:

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is primarily managed through diet and lifestyle modifications. However, these behavioural interventions alone may not achieve disease regression or remission, and maintaining long‐term adherence is challenging. Incretin mimetics and other gastrointestinal hormones targeting the pleiotropic pathophysiological pathways underlying MASLD have now emerged as promising disease‐modifying therapies.

Aims:

This is a comprehensive review summarising the role of glucagon‐like peptide‐1 (GLP‐1) receptor agonists and glucagon/glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor dual or triple agonists in the treatment of metabolic dysfunction‐associated steatohepatitis (MASH).

Methods:

Only clinical trials with endpoints assessed by liver histology were included for a robust evaluation of therapeutic efficacy.

Results:

Recent evidence from phase 2 clinical trials for MASH demonstrated that pharmacological agents based on GLP‐1 receptor agonism are effective in improving disease activity. Additionally, tirzepatide and survodutide showed potential clinical benefits in reducing fibrosis. Other cardiometabolic benefits observed include weight loss and improvements in glycaemic control and lipid profile. Adherence to treatment may be limited by gastrointestinal side effects, though they were found to be generally mild to moderate in severity. An interim analysis of the semaglutide phase 3 trial confirmed its efficacy in improving steatohepatitis and demonstrated its potential to improve fibrosis.

Conclusions:

GLP‐1 receptor agonists, alone or in combination with GIP and/or glucagon receptor agonists, represent promising, effective pharmacotherapies for the treatment of MASLD/MASH. Larger and longer‐duration clinical trials are needed to further evaluate the efficacy and safety of GIP receptor and glucagon receptor agonism.

01 May 2025·PEPTIDES

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Review

Author: Flatt, Peter R ; Conlon, J Michael ; Bailey, Clifford J

Recent studies with peptide-based incretin therapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the dual agonist tirzepatide that engages receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials and 'real-world' studies have confirmed the marked glucose-lowering and weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young and elderly individuals with and without diabetes and/or overweight or obesity. Recent studies have also confirmed protections against the development and progression of cardiovascular and renal diseases that are additive to the benefits conferred by improved control of blood glucose and body weight. Emerging evidence suggests that incretin therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea and possibly degenerative bone disorders and cognitive decline. New incretin-based peptide therapies in development include a long-acting glucagon receptor agonist (LY3324954), dual GLP-1/glucagon receptor agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon receptor agonists (retatrutide, efocipegtrutide), a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), a unimolecular GLP-1/amylin receptor dual agonist (amycretin), and a GIP receptor antibody with GLP-1 receptor agonism (MariTide). The creation of multi-targeting incretin-based synthetic peptides provides opportunities for improved management of type 2 diabetes and obesity as well as new therapeutic approaches to an expanding list of associated co-morbidities. The aim of the review is to acquaint the reader with developments in the field from 2023 to the present (February 2025).

01 Apr 2025·DIABETES OBESITY & METABOLISM

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m² in the phase 2 trial of survodutide, a glucagon/GLP‐1 receptor dual agonist

Article

Author: Hussain, Samina Ajaz ; Lucas, Kathryn J. ; le Roux, Carel W. ; Steen, Oren ; Startseva, Elena ; Unseld, Anna ; Hennige, Anita M.

Abstract:

Aim:

To explore the effects of sex and baseline body mass index (BMI) on the efficacy and safety of survodutide in people with a BMI ≥27 kg/m2.

Materials and Methods:

Totally 387 people (aged 18–75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once‐weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20‐week dose escalation; 26‐week dose maintenance). Participants were categorized according to sex and baseline BMI. Data were analysed descriptively for the full analysis set (FAS), according to dose assigned at randomization (planned treatment) using on‐treatment data or all data censored for COVID‐19‐related treatment discontinuations. (ClinicalTrials.gov number: NCT04667377).

Results:

After 46 weeks of survodutide treatment, females had greater reductions in bodyweight and waist circumference than males. Participants with a lower baseline BMI had greater proportional reductions in bodyweight than those with a higher baseline BMI; the trend was reversed for reductions in waist circumference. Rates of adverse events (AEs) were comparable between subgroups for sex and baseline BMI. Nausea was the most frequently reported gastrointestinal AE in all subgroups.

Conclusions:

In people with a BMI ≥27 kg/m2, survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI, and was tolerated at all doses tested.

120

News (Medical) associated with Survodutide

07 Apr 2025

·www.biospace.com

7 Late-Stage MASH Candidates That Could Reshape the Market

iStock, Elena Merkulova Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by 2033. It’s been a little more than a year since the FDA approved Madrigal Pharmaceuticals’ Rezdiffra as the first treatment for the liver disease metabolic dysfunction-associated steatohepatitis. After earning $180 million in full-year 2024 sales , Madrigal expects Rezdiffra to reach blockbuster status in the coming years. With an estimated 22 million Americans living with metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic steatohepatitis (NASH)—there is a growing pipeline of potential therapies, and several companies are expecting Phase III readouts in 2025. Rather than relying on one strategy, the leading candidates are approaching the disease from different angles. This could allow more assets to carve out a share of a market that is expected to be worth $16 billion by 2033 . Rezdiffra’s early success, along with clinical research suggesting that GLP-1 drugs could also have therapeutic potential in MASH, has analysts optimistic about the growth potential of the space. “That’s why Rezdiffra has been so heavily watched and why there are so many drugs in development for MASH,” Edward Nash, senior biotechnology analyst at Canaccord Genuity, told BioSpace . “It’s thought of as having the potential to be the next type 2 diabetes for the industry. It’s that big of a metabolic disease, and it offers multi-billion dollar opportunities for many different treatment mechanisms.” Here, BioSpace looks at five candidates that could soon emerge on the market. 89bio’s Pegozafermin Fibroblast growth factor 21 analog Currently undergoing Phase III trials , 89bio’s pegozafermin is part of a class of treatments for MASH that mimics the activity of fibroblast growth factor 21 (FGF21), a hormone produced by the liver that acts as a metabolic regulator. According to Nash, FGF21 analogs have generated the most attention because they’ve shown a “really strong ability to reduce liver fibrosis,” which is damage to the liver caused by the chronic inflammation associated with MASH. So far, pegozafermin is no exception. Phase IIb trial results showed the candidate managed at least one-stage fibrosis improvement at two different dosage levels (30 mg weekly and 44 mg every-other week) without worsening of MASH. In addition, MASH resolution without worsening of fibrosis was managed at 26% and 23%, dependent on the dosage. Rohan Palekar, CEO of 89bio, pointed to a recent peer-reviewed publication where pegozafermin was ranked as the most efficacious drug for fibrosis improvement and MASH resolution among all approved or investigational MASH drugs. “A key distinction is that pegozafermin has also shown a favorable safety and tolerability profile, with few gastrointestinal side effects and no clinically significant effect on bone density,” Palekar told BioSpace in an email. Akero Therapeutics’ Efruxifermin Fibroblast growth factor 21 analog Akero finds itself in a similar position to 89bio, with a FGF21 analog in Phase III trials. However, the biotech’s path to this point, at least from a shareholder perspective, has been more tumultuous. Akero’s stock price sunk in October 2023 after efruxifermin missed its primary endpoint of 36-week fibrosis improvement in a Phase IIb trial. The drug’s prospects were saved five months later when the biotech was able to show in 96-week data that fibrosis was significantly improved in patients with MASH. “Unlike other MASH drugs that target [a] specific pathway, efruxifermin delivers sustained FGF21 signaling to both liver and adipose tissue, aiming to correct metabolic imbalances that drive disease progression,” Kitty Yale, chief development officer at Akero, told BioSpace over email. “While some obesity drugs aid weight loss, they may not directly target the liver, limiting their impact on fibrosis.” The biotech has a Phase III program comprising three ongoing clinical trials aimed at supporting future regulatory applications of efruxifermin for patients with compensated cirrhosis due to MASH and with pre-cirrhotic MASH, Yale added. Boehringer Ingelheim, Eli Lilly, Novo Nordisk: Survodutide, Tirzepatide, Semaglutide GLP-1 agonists A fierce competition is underway between weight loss rivals, as GLP-1 drug developers attempt to differentiate their treatments . One strategic angle has been to target MASH as an additional indication to support the drugs’ widespread use. According to Nash, an approval in MASH would boost GLP-1s’ appeal for physicians because it would allow them to address three metabolic diseases—type 2 diabetes, obesity and MASH—with the same treatment. Boehringer Ingelheim, Eli Lilly and Novo Nordisk have all adopted this approach. Boehringer and Novo Nordisk have progressed survodutide and semaglutide , respectively, through to Phase III trials, and Lilly posted positive Phase II trial results for tirzepatide in June 2024. Of the GLP-1s currently being studied for MASH, Nash suggested that semaglutide is the closest to potential FDA approval, projecting that an approval could come by the end of 2025 or in the early part of 2026. While clinical trials have indicated that GLP-1s can reduce fat in the liver, that does not necessarily indicate that fibrosis will also be reduced, Nash cautioned. Due to this limitation, GLP-1 drug developers will likely explore combination therapies, which could see other approaches to MASH combined with GLP-1 medicines, he added. Both Palekar and Yale said they are exploring using their MASH candidates in conjunction with GLP-1s. Boston Pharmaceuticals’ Efimosfermin Alfa Fibroblast growth factor 21 analog Boston Pharmaceuticals’ FGF21 analog is a little bit different. A fusion protein based on human IgG and FGF21, efimosfermin alfa is longer-acting than other late-stage rivals in the MASH pipeline, with Boston exploring a once-monthly regimen for the drug. In November 2024, the potential treatment elicited a one-stage improvement in fibrosis without worsening of MASH in a Phase II trial . The biotech plans to advance efimosfermin into Phase III trials in the fourth quarter of this year, according to CEO Sophie Kornowski. Similar to other companies working in the space, the next stage of trials will assess how efimosfermin pairs with incretin treatments for diabetes, such as GLP-1s, Kornowski told BioSpace via email. Nash likened Boston’s dosing to approaches in immunology and inflammation, where when rival drugs’ clinical outcomes are similar and the longer dosing schedule drugs are preferred. Margaret Koziel, chief medical officer at Boston, told BioSpace by email that efimosfermin’s increased half-life is enabled by “several point mutations and an additional disulfide bond that prevents proteolytic degradation.” Viking Therapeutics’ VK2809 Thyroid hormone receptor agonist Adopting a similar approach to Madrigal, Viking has a thyroid hormone receptor agonist as its lead candidate for MASH. The biotech posted positive Phase IIb data in November 2024 showing that up to 75% of patients treated with VK2809 reached MASH resolution without fibrosis worsening. A further 57% showed at least a one-stage improvement in fibrosis without deterioration of MASH. Like Rezdiffra, VK2809 is a small molecule, oral treatment. In Phase II studies, Viking carried out both a daily and an every-other-day dosing schedule. In full-year results released in February 2025 , Viking stated that it considered its drug candidate “best-in-class” but only noted that it is “currently evaluating potential next steps” for VK2809. Should the development of VK2809 prove successful, the biotech could explore trialing the treatment alongside its own GLP-1 treatment candidate, VK2735, providing Viking with an in-house combination therapy. Despite this healthy roster of candidates, Nash said it is unlikely that any of them will be able to fully displace Rezdiffra. “Given their lead over the competitive landscape and being on the market first, Madrigal is going to have entrenched itself by the time competitors arrive,” he concluded. “Plus, it’s a safe drug—so, it’s a nice, solid foundational drug to have on the market.”

Clinical ResultPhase 2Phase 3

12 Mar 2025

·www.pharmaceutical-technology.com

Zealand and Roche strike $5.3bn obesity treatment deal

Zealand first announced that it was seeking a development partner in August 2024. Credit: Liudmila Chernetska via Getty Images. Zealand Pharma has named Roche as a development and commercialisation partner for its lead obesity candidate petrelintide, after a seven-month search. Under the deal, Zealand will receive an upfront payment of $1.65bn, with the potential for milestone payments bringing the total deal value to $5.3bn, depending on Phase III trials and commercial performance. Zealand and Roche will co-develop and co-commercialise Zealand’s amylin analogue petrelintide as a monotherapy, and in combination therapies. The first planned combination will pair petrelintide with Roche’s glucagon-like peptide 1/gastric inhibitory polypeptide (GLP-1/GIP) agonist candidate CT-388. Inherited by Roche through its $2.7bn acquisition of Carmot Therapeutics, CT-388 has demonstrated efficacy in early trials . In a Phase Ib trial (NCT04838405), participants taking the therapy achieved a mean placebo-adjusted weight loss of 18.8% at 24 weeks. CT-388 is currently being studied in two Phase IIb clinical trials in people with overweight/obesity with (NCT06628362) and without type 2 diabetes (NCT06525935). As part of the collaboration, Zealand will contribute $350m to support the study of the CT-388/petrelintide combo. The companies will share profits and losses on a 50/50 basis in the US and Europe while Zealand will receive tiered royalties on net sales in other global markets. Zealand first shared that it was eyeing up a partner to study and commercialise its lead weight loss candidate back in August 2024. However, its failure to announce a deal in its February earnings report last month disappointed investors . At the time, CEO Adam Steensberg reassured stakeholders that the company was “exactly where it wants to be in the process”. Zealand has delivered this promise with the Roche partnership now secured. The collaboration marks Zealand’s progression into the obesity space, which is dominated by GLP-1 receptor agonists (GLP-1RAs) such as Novo Nordisk’s semaglutide (branded as Wegovy and Ozempic), and Eli Lilly’s tirzepatide (branded as Mounjaro and Zepbound). Petrelintide is currently being investigated in the Phase II ZUPREME clinical trial (NCT06662539). While GLP-1RAs such as semaglutide work by stimulating insulin secretion, reducing glucagon levels, and slowing gastric emptying, amylin analogues such as petrelintide act through a different mechanism. By mimicking the hormone amylin, they suppress glucagon secretion, slow gastric emptying, and restore sensitivity to the satiety hormone leptin. Zealand believes this distinct mode of action could position petrelintide as a best-in-class therapy in obesity and diabetes. “We strongly believe that petrelintide holds potential as a foundational therapy for weight management,” said Steensberg in the 12 March announcement accompanying the deal. Investor confidence in Zealand’s obesity pipeline has remained high. In June 2024, the company raised $1bn through a share offering, surpassing its original target of $900m. In January 2024, Zealand secured an additional DKr1.45bn ($204m) in funding for its obesity pipeline through a private placement and directed share issue to US investment firms. Zealand’s other major obesity candidate , survodutide, a glucagon/GLP-1 receptor dual agonist developed with Boehringer Ingelheim, is already in Phase III trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Rates of obesity across populations are increasing, and the market for obesity drugs is set to reach $37.1bn across the seven major markets (US, UK, Germany, France, Italy, Spain, and Japan), by 2031, according to a GlobalData report. GlobalData is the parent company of Pharmaceutical Technology.

Phase 1Phase 2Clinical ResultPhase 3Acquisition

20 Feb 2025

·endpts.com

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

Investors who were eager for news of a partnering deal for the Zealand Pharma’s mid-stage asset petrelintide had a disappointing Thursday morning: The company reported 2024 results without a big pharma signing up. “We are exactly where we want to be,” Zealand CEO Adam Steensberg told Endpoints News in an interview, dismissing the notion that potential partners are waiting for data from the ongoing Phase 2b trial of petrelintide, due in the first half of this year. The group’s 2024 revenues were 62.7 million Danish kroner ($8.8 million), down 82% from 2023. This is because 2023’s figure was buoyed by milestone payments, most notably $30 million from Boehringer Ingelheim. Still, the biotech is well-capitalized, having raised $1 billion last year. Steensberg declined to say whether any milestones might come in 2025, though he did say that if a petrelintide partnership were to happen, it would “provide a pretty significant upfront.” But a deal has been slow — the group has been seeking a partner for the amylin analog for around a year. Steensberg said this is not so much because of big companies’ reluctance, but because of its own determination to sign up the right collaborator. The ideal partner would be one of the 10 biggest pharma companies, with “a vision of winning in this space in the future, and not just playing.” This is a big ask now that Novo Nordisk and Eli Lilly are already way ahead of any competition. In fact, these two companies are the only ones that Zealand believes would not be interested in a deal for petrelintide. More remarkably, Steensberg said a partner would have to share Zealand’s belief that amylin analogs will become “foundational” obesity therapies, meaning that they could eventually become the largest category within weight management, outpacing GLP-1s. This is despite the late-stage disappointment with Novo’s amylin/GLP-1 combo CagriSema. Steensberg said this had no effect on Zealand’s partnering discussions. “If anything, it just underscored what we have been saying for a long time,” he said. “If you ask patients, most are not looking for 25 to 30% weight loss. Most are looking for 15 to 20% weight loss.” Instead, it is petrelintide’s expected better tolerability that could lure patients away from the current GLP-1s, Novo’s Wegovy and Lilly’s Zepbound. “That’s hugely important when you think not just about weight loss, but also weight maintenance,” Steensberg said. Once patients are in the maintenance stage, they will not put up with unpleasant side effects, he added. “I actually, personally think there will be more obese individuals who have tried a GLP-1 and said, ‘never again.’” Steensberg does not believe that an oral therapy will be necessary to do well in the maintenance setting. All of Zealand’s obesity therapies — it has two clinical-stage assets aside from petrelintide — are injected. “If it’s an oral small molecule GLP-1, I actually think the patient experience is going to be significantly worse than on an injectable because of the tolerability issues,” he said, pointing out that GLP-1 pills must be dosed at much higher levels than shots because of the molecules’ low oral bioavailability. But the company has not one but two GLP-1-based drugs in the clinic. The most advanced is survodutide, a GLP-1/glucagon agonist partnered with Boehringer, which is in late-stage trials in both obesity and the fatty liver disease called MASH. Zealand is hoping for around 20% weight loss in the SYNCHRONIZE-1 obesity study, but Steensberg says the key differentiator for survodutide will be its effects in MASH. Boehringer has started two massive trials here, in a total of nearly 3,400 patients. It has not been said when these will report, but Steensberg said that Boehringer expects the product to be on the market in 2027 or 2028 “in either obesity or MASH.” This, at least, will trigger a milestone. Editor’s note: This article was updated to correct the expected date of the petrelintide Phase 2b readout.

Phase 2

100 Deals associated with Survodutide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cirrhosis, Cryptogenic	Phase 3	United States	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Japan	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Argentina	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Australia	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Austria	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Belgium	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Brazil	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Bulgaria	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Canada	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024
Cirrhosis, Cryptogenic	Phase 3	Chile	Boehringer Ingelheim (China) Investment Co., Ltd.	12 Nov 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04771273 (1404-0043, CTgov)	Phase 2	Nonalcoholic Steatohepatitis	295	Survodutide (Survodutide 2.4 mg - Planned Maintenance Treatment)	uqurxbkpbd = miwimmtxwv ffmblirdjo (bfsyyjpawb, gspvegjilb - cxzrsulnwj) View more	-	03 Dec 2024
				Survodutide (Survodutide 4.8 mg - Planned Maintenance Treatment)	uqurxbkpbd = rrfpousvqq ffmblirdjo (bfsyyjpawb, ptkrvaqtje - isuduvakks) View more
ESC2024	Phase 2	Obesity	387	Survodutide 4.8 mg	xmpgseidil(cpjescwhzq) = ntzrqxwxld ilkzhofiso (azcneflxfu )	Positive	01 Sep 2024
NCT04153929 \| NCT03591718 \| NCT04667377 (1665-P, ADA2024)	Phase 1/2	Diabetes Mellitus, Type 2 \| Obesity HbA1c \| insulin sensitivity \| glucose biomarkers ... View more	-	Survodutide	smhhfcwvfj(smqhbganvk) = 0.4 vs 0.0 bmvuffhgap (adgovgarxf ) View more	Positive	14 Jun 2024
				Placebo
NCT04771273 (1404-0043, Pubmed)	Phase 2	Nonalcoholic Steatohepatitis	293	Survodutide 2.4 mg	jjivvpxpjb(zzrtqswjwi) = kuejhzbwmi xreaorazic (umzdqfryim ) View more	Positive	07 Jun 2024
				Survodutide 4.8 mg	jjivvpxpjb(zzrtqswjwi) = nbeuokkdvl xreaorazic (umzdqfryim ) View more
NCT04667377 (Phase II Trial, ENDO2024)	Phase 2	Overweight \| Obesity	384	Survodutide 4.8 mg	yqapcoczce(egplncqwzk) = iirpdiohgg otlpsvgwlg (owptbbvgbt )	Positive	01 Jun 2024
				Placebo	yqapcoczce(egplncqwzk) = zpaacgpmcr otlpsvgwlg (owptbbvgbt )
NCT04771273 (Corporate Publications) Manual	Phase 2	Metabolic dysfunction-associated steatotic liver disease	295	Survodutide	itvhuhckio(xmzgoqfxkq) = qivknrczkz prdacjhsqi (kaugiqsycu ) Met	Positive	26 Feb 2024
				placebo	itvhuhckio(xmzgoqfxkq) = jaoucappsv prdacjhsqi (kaugiqsycu ) Met
NCT04771273 (GlobeNewswire) Manual	Phase 3	Nonalcoholic Steatohepatitis	-	survodutide	feqpaoujyr(tugjukzgwh) = cplzcqifrh ltmfscarrb (bfxtfznqmr ) Met	Positive	26 Feb 2024
				Placebo	feqpaoujyr(tugjukzgwh) = mynvkvrmeq ltmfscarrb (bfxtfznqmr ) Met
NCT04667377 (Phase II Trial, CTgov)	Phase 2	Obesity	387	BI 456906 (0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation))	zzpzwjymbi(kbpxkxkldn) = whcqebekoc ahqdmbksyj (illnadxgzu, 1.07) View more	-	02 Nov 2023
				BI 456906 (2.4 mg BI 456906 - Planned Maintenance Treatment)	zzpzwjymbi(kbpxkxkldn) = bvwwwndlet ahqdmbksyj (illnadxgzu, 1.01) View more
NCT04667377 (ADA2023) Manual	Phase 2	Overweight \| Obesity	387	BI 456906 0.6 mg	gamfqdvxxt(bmurmjevtl) = gntlafdbxb mzjckbelvs (psvbcqgxdt ) View more	Positive	23 Jun 2023
				BI 456906 2.4 mg	gamfqdvxxt(bmurmjevtl) = ubpizpxdko mzjckbelvs (psvbcqgxdt ) View more
NCT04153929 (Phase II, CTgov)	Phase 2	Diabetes Mellitus, Type 2	413	Placebo (Placebo)	dacxhqhtsr(lrpnaxjgec) = avrfsjrkyf dkdrujmaci (rhhhrwqaiu, 0.81) View more	-	29 Nov 2022
				BI 456906 (BI 456906 0.3 mg)	dacxhqhtsr(lrpnaxjgec) = nxwgnabhuf dkdrujmaci (rhhhrwqaiu, 0.71) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis